CXCR4 and HIV-1 infection: GPR15LG showed dose-dependent inhibition of CXCR4-tropic HIV-1 infection (IC50 = 5.9 ± 0.54 μM) but had no effect on CCR5-tropic HIV-1, further confirming its specificity for CXCR4.